Prognostic gene expression signature for high-grade serous ovarian cancer
dc.contributor.author | Millstein, J. | |
dc.contributor.author | Budden, Timothy | |
dc.contributor.author | Goode, E. L. | |
dc.contributor.author | Anglesio, M. S. | |
dc.contributor.author | Talhouk, A. | |
dc.contributor.author | Intermaggio, M. P. | |
dc.contributor.author | Leong, H. S. | |
dc.contributor.author | Chen, S. | |
dc.contributor.author | Elatre, W. | |
dc.contributor.author | Gilks, B. | |
dc.contributor.author | Nazeran, T. | |
dc.contributor.author | Volchek, M. | |
dc.contributor.author | Bentley, R. C. | |
dc.contributor.author | Wang, C. | |
dc.contributor.author | Chiu, D. S. | |
dc.contributor.author | Kommoss, S. | |
dc.contributor.author | Leung, S. C. Y. | |
dc.contributor.author | Senz, J. | |
dc.contributor.author | Lum, A. | |
dc.contributor.author | Chow, V. | |
dc.contributor.author | Sudderuddin, H. | |
dc.contributor.author | Mackenzie, R. | |
dc.contributor.author | George, J. | |
dc.contributor.author | Fereday, S. | |
dc.contributor.author | Hendley, J. | |
dc.contributor.author | Traficante, N. | |
dc.contributor.author | Steed, H. | |
dc.contributor.author | Koziak, J. M. | |
dc.contributor.author | Kobel, M. | |
dc.contributor.author | McNeish, I. A. | |
dc.contributor.author | Goranova, T. | |
dc.contributor.author | Ennis, D. | |
dc.contributor.author | Macintyre, G. | |
dc.contributor.author | Silva, D. | |
dc.contributor.author | Ramon, Y. C. T. | |
dc.contributor.author | Garcia-Donas, J. | |
dc.contributor.author | Polo, S. H. | |
dc.contributor.author | Rodriguez, G. C. | |
dc.contributor.author | Cushing-Haugen, K. L. | |
dc.contributor.author | Harris, H. R. | |
dc.contributor.author | Greene, C. S. | |
dc.contributor.author | Zelaya, R. A. | |
dc.contributor.author | Behrens, S. | |
dc.contributor.author | Fortner, R. T. | |
dc.contributor.author | Sinn, P. | |
dc.contributor.author | Herpel, E. | |
dc.contributor.author | Lester, J. | |
dc.contributor.author | Lubinski, J. | |
dc.contributor.author | Oszurek, O. | |
dc.contributor.author | Toloczko, A. | |
dc.contributor.author | Cybulski, C. | |
dc.contributor.author | Menkiszak, J. | |
dc.contributor.author | Pearce, C. L. | |
dc.contributor.author | Pike, M. C. | |
dc.contributor.author | Tseng, C. | |
dc.contributor.author | Alsop, J. | |
dc.contributor.author | Rhenius, V. | |
dc.contributor.author | Song, H. | |
dc.contributor.author | Jimenez-Linan, M. | |
dc.contributor.author | Piskorz, A. | |
dc.contributor.author | Gentry-Maharaj, A. | |
dc.contributor.author | Karpinskyj, C. | |
dc.contributor.author | Widschwendter, M. | |
dc.contributor.author | Singh, N. | |
dc.contributor.author | Kennedy, C. J. | |
dc.contributor.author | Sharma, R. | |
dc.contributor.author | Harnett, P. R. | |
dc.contributor.author | Gao, B. | |
dc.contributor.author | Johnatty, S. E. | |
dc.contributor.author | Sayer, R. | |
dc.contributor.author | Boros, J. | |
dc.contributor.author | Winham, S. J. | |
dc.contributor.author | Keeney, G. L. | |
dc.contributor.author | Kaufmann, S. H. | |
dc.contributor.author | Larson, M. C. | |
dc.contributor.author | Luk, H. | |
dc.contributor.author | Hernandez, B. Y. | |
dc.contributor.author | Thompson, P. J. | |
dc.contributor.author | Wilkens, L. R. | |
dc.contributor.author | Carney, M. E. | |
dc.contributor.author | Trabert, B. | |
dc.contributor.author | Lissowska, J. | |
dc.contributor.author | Brinton, L. | |
dc.contributor.author | Sherman, M. E. | |
dc.contributor.author | Bodelon, C. | |
dc.contributor.author | Hinsley, S. | |
dc.contributor.author | Lewsley, L. A. | |
dc.contributor.author | Glasspool, R. | |
dc.contributor.author | Banerjee, S. N. | |
dc.contributor.author | Stronach, E. A. | |
dc.contributor.author | Haluska, P. | |
dc.contributor.author | Ray-Coquard, I. | |
dc.contributor.author | Mahner, S. | |
dc.contributor.author | Winterhoff, B. | |
dc.contributor.author | Slamon, D. | |
dc.contributor.author | Levine, D. A. | |
dc.contributor.author | Kelemen, L. E. | |
dc.contributor.author | Benitez, J. | |
dc.contributor.author | Chang-Claude, J. | |
dc.contributor.author | Gronwald, J. | |
dc.contributor.author | Wu, A. H. | |
dc.contributor.author | Menon, U. | |
dc.contributor.author | Goodman, M. T. | |
dc.contributor.author | Schildkraut, J. M. | |
dc.contributor.author | Wentzensen, N. | |
dc.contributor.author | Brown, R. | |
dc.contributor.author | Berchuck, A. | |
dc.contributor.author | Chenevix-Trench, G. | |
dc.contributor.author | deFazio, A. | |
dc.contributor.author | Gayther, S. A. | |
dc.contributor.author | Garcia, M. J. | |
dc.contributor.author | Henderson, M. | |
dc.contributor.author | Rossing, M. A. | |
dc.contributor.author | Beeghly-Fadiel, A. | |
dc.contributor.author | Fasching, P. A. | |
dc.contributor.author | Orsulic, S. | |
dc.contributor.author | Karlan, B. Y. | |
dc.contributor.author | Konecny, G. E. | |
dc.contributor.author | Huntsman, D. G. | |
dc.contributor.author | Bowtell, D. D. | |
dc.contributor.author | Brenton, J. D. | |
dc.contributor.author | Doherty, J. A. | |
dc.contributor.author | Pharoah, P. D. P. | |
dc.contributor.author | Ramus, S. J. | |
dc.date.accessioned | 2020-06-16T11:03:21Z | |
dc.date.available | 2020-06-16T11:03:21Z | |
dc.date.issued | 2020 | en |
dc.identifier.citation | J. Millstein, T. Budden, E. L. Goode et al. Prognostic gene expression signature for high-grade serous ovarian cancer. Ann Oncol. 2020. | en |
dc.identifier.pmid | 32473302 | en |
dc.identifier.doi | 10.1016/j.annonc.2020.05.019 | en |
dc.identifier.uri | http://hdl.handle.net/10541/623058 | |
dc.description.abstract | BACKGROUND: Median overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is approximately four years, yet survival varies widely between patients. There are no well-established, gene expression signatures associated with prognosis. The aim of this study was to develop a robust prognostic signature for overall survival in HGSOC patients. PATIENTS AND METHODS: Expression of 513 genes, selected from a meta-analysis of 1455 tumours and other candidates, were measured using NanoString technology from formalin-fixed, paraffin-embedded (FFPE) tumour tissue from 3,769 women with HGSOC from multiple studies. Elastic net regularization for survival analysis was applied to develop a prognostic model for 5-year OS, trained on 2702 tumours from fifteen studies and evaluated on an independent set of 1067 tumours from six studies. RESULTS: Expression levels of 276 genes were associated with OS [false discovery rate (FDR) < 0.05] in covariate-adjusted single gene analyses. The top five genes were TAP1, ZFHX4, CXCL9, FBN1, and PTGER3 (P < 0.001). The best performing prognostic signature included 101 genes enriched in pathways with treatment implications. Each gain of one standard deviation in the gene expression score (GES) conferred a greater than two-fold increase in risk of death [HR = 2.35 (2.02, 2.71); P < 0.001]. Median survival by GES quintile was 9.5 (8.3, --), 5.4 (4.6, 7.0), 3.8 (3.3, 4.6), 3.2 (2.9, 3.7) and 2.3 (2.1, 2.6) years. CONCLUSION: The OTTA-SPOT (Ovarian Tumor Tissue Analysis consortium - Stratified Prognosis of Ovarian Tumours) gene expression signature may improve risk stratification in clinical trials by identifying patients who are least likely to achieve 5-year survival. The identified novel genes associated with the outcome may also yield opportunities for the development of targeted therapeutic approaches. | en |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.1016/j.annonc.2020.05.019 | en |
dc.title | Prognostic gene expression signature for high-grade serous ovarian cancer | en |
dc.type | Article | en |
dc.contributor.department | Division of Biostatistics, Department of Preventive Medicine, Keck School of Medicine. University of Southern California. Los Angeles | en |
dc.identifier.journal | Annals of Oncology | en |
dc.description.note | en] | |
refterms.dateFOA | 2020-06-16T14:31:34Z |